

Astellas Announces Consolidated Business Forecasts for Fiscal Year 2014

Tokyo, April 23, 2015 – Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced the consolidated business forecasts (IFRS) for the fiscal year 2014 ended March 2015 (April 1, 2014-March 31, 2015) as follows.

1. Consolidated business forecasts for fiscal year 2014 (full basis)

The Company disclosed the following business forecasts (full basis) for the fiscal year 2014 because the profits at each stage are expected to increase over 30% compared to the results from previous year. The Company had not disclosed forecasts on a full basis except for sales.

Consolidated business forecasts for fiscal year 2014 (full basis)

| | Sales | Operating profit | Profit before tax | Profit for the year | Profit attributable to owners of the parent | Earnings per share |
|--------------------------------|------------------|------------------|-------------------|---------------------|---|--------------------|
| Results from previous year (A) | Million yen | Million yen | Million yen | Million yen | Million yen | Yen |
| | 1,139,909 | 116,806 | 121,975 | 90,874 | 90,874 | 40.45 |
| Current forecast (B) | 1,247,259 | 185,663 | 189,683 | 135,856 | 135,856 | 61.50 |
| Change (B – A) | 107,351 | 68,858 | 67,708 | 44,982 | 44,982 | |
| Change (%) | 9.4% | 59.0% | 55.5% | 49.5% | 49.5% | |

2. Analysis for consolidated business forecasts (full basis)

Sales are expected to increase from the previous year due to global expansion of XTANDI for the treatment of prostate cancer and overactive bladder (OAB) treatments Vesicare and Betanis/ Myrbetriq/ BETMIGA.

Gross profit is expected to increase compared to the previous fiscal year as increased sales and a fall in the cost-to-sales ratio are expected. Selling, general and administrative expenses and research and development expenses are expected to increase year-on-year. “Other expense” excluded from the results on a core basis are expected to be 43.3 billion yen (previous fiscal year: 81.0 billion yen).

As a result, operating profit, profit before tax and profit for the year are expected to increase on a full basis.

3. Revision of consolidated business forecasts for fiscal year 2014 (core basis)

The Company discloses business results on a core basis as an indicator of its recurring profitability. The Company revised the forecasts for the fiscal year 2014 on a core basis as of October 31, 2014. Details are shown below.

Consolidated business forecasts for fiscal year 2014 (core basis)

| | Sales | Core Operating profit | Core Profit for the year | Core Earnings per share |
|---|--------------------------|------------------------|--------------------------|-------------------------|
| Previous forecast (A) | Million yen 1,210,000 | Million yen 210,000 | Million yen 154,000 | Yen 69.65 |
| Current forecast (B) | 1,247,259 | 216,500 | 153,244 | 69.37 |
| Change (B – A) | 37,259 | 6,500 | -756 | |
| Change (%) | 3.1% | 3.1% | -0.5% | |
| (reference) Results from previous year | 1,139,909 | 186,253 | 132,796 | 59.11 |

4. Reasons for Revision

Sales are expected to exceed the previous forecast due to global expansion of XTANDI and OAB treatments Vesicare and Betanis/ Myrbetriq/ BETMIGA.

While increases in selling, general and administrative expenses and research and development expenses are expected, operating profit on a core basis is expected to exceed the previous forecast due to an increase in gross profit with the increase in sales. Profit for the year on a core basis is expected to be lower than the previous forecast as the income tax burden rate is predicted to increase to a higher level than previously expected.

The Company will announce the consolidated business forecasts for the fiscal year 2015 ended March 2016 (April 1, 2015-March 31, 2016) on a full basis as well as a core basis on May 11, 2015.

(Note) The above forecasted consolidated business results are based on information available as of the date of the announcement and may differ from final figures.